The global liver cancer diagnostics market value was US$ 9.7 billion in 2020. The global liver cancer diagnostics market value is forecast to reach US$ 20.9 billion by 2030, growing at a compound annual growth rate (CAGR) of 8% during the forecast period from 2021-2030.
Cancer of the liver begins in the cells of the liver. Several types of cancer can occur in the liver. Hepatocellular carcinoma is the most common type of liver cancer, which begins in the main liver cell type (hepatocyte). Hepatoblastoma and intrahepatic cholangiocarcinoma are less common types of liver cancer.
Factors Influencing Market Growth
Impact Analysis of COVID-19
The COVID-19 pandemic had a negative effect on the global liver cancer diagnostics market. A fall in the number of patients visiting cancer hospitals and clinics due to the pandemic has greatly affected revenues, as has a change in care approach for emergency cases and critically ill COVID-19 patients. As a result of COVID-19, hospital visits for liver cancer diagnostics have decreased. It is mainly because of the low number of healthcare professionals available in the country.
Regional Insights
In 2020, North America accounted for the largest revenue share of the liver cancer diagnostics market, and it is forecast to remain dominant throughout the forecast period. Health insurance policies, well-established infrastructure, and the use of innovative diagnostic tests account for the region's dominance. Additionally, the local presence of leading players and their ongoing strategic initiatives contribute to regional growth. As a result of the high prevalence of hepatocellular carcinoma in North America, the U.S. dominates the market share.
Over the study period, liver cancer diagnostics is forecast to display the highest growth in the Asia Pacific. Due to the high prevalence of Hepatitis in emerging countries like India and China, this growth is high. Further, government initiatives to increase awareness about early detection of liver cancer and rising consumption of alcohol and tobacco contribute to market growth.
Leading Competitors
The leading prominent companies profiled in the global liver cancer diagnostics market are:
Scope of the Report
The global liver cancer diagnostics market segmentation focuses on Test Type, End-use, and Region.
Segmentation based on Test Type
Segmentation based on End-Use
Segmentation based on Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL LIVER CANCER DIAGNOSTICS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
4 GLOBAL LIVER CANCER DIAGNOSTICS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS
5 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE
5.1 OVERVIEW
5.2 LABORATORY TESTS
5.2.1 BIOMARKERS
5.2.1.1 ONCOFETAL AND GLYCOPROTEIN ANTIGENS
5.2.1.2 ENZYMES AND ISOENZYMES
5.2.1.3 GROWTH FACTORS AND RECEPTORS
5.2.1.4 MOLECULAR MARKERS
5.2.1.5 PATHOLOGICAL BIOMARKERS
5.2.2 BLOOD TESTS
5.3 IMAGING TESTS
5.4 ENDOSCOPY
5.5 BIOPSY
5.6 OTHERS
6 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY END-USE
6.1 OVERVIEW
6.2 HOSPITALS & DIAGNOSTIC LABORATORIES
6.3 ACADEMIC & RESEARCH INSTITUTES
6.4 PHARMACEUTICAL & CRO LABORATORIES
7 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY
7.1 OVERVIEW
7.2 NORTH AMERICA
7.2.1 NORTH AMERICA MARKET SNAPSHOT
7.2.2 U.S.
7.2.3 CANADA
7.2.4 MEXICO
7.3 EUROPE
7.3.1 EUROPE MARKET SNAPSHOT
7.3.2 WESTERN EUROPE
7.3.2.1 THE UK
7.3.2.2 GERMANY
7.3.2.3 FRANCE
7.3.2.4 ITALY
7.3.2.5 SPAIN
7.3.2.6 REST OF WESTERN EUROPE
7.3.3 EASTERN EUROPE
7.3.3. 1 POLAND
7.3.3.2 RUSSIA
7.3.3.3 REST OF EASTERN EUROPE
7.4 ASIA PACIFIC
7.4.1 ASIA PACIFIC MARKET SNAPSHOT
7.4.2 CHINA
7.4.3 JAPAN
7.4.4 INDIA
7.4.5 AUSTRALIA & NEW ZEALAND
7.4.6 ASEAN
7.4.7 REST OF ASIA PACIFIC
7.5 MIDDLE EAST & AFRICA
7.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
7.5.2 UAE
7.5.3 SAUDI ARABIA
7.5.4 SOUTH AFRICA
7.5.5 REST OF MEA
7.6 SOUTH AMERICA
7.6.1 SOUTH AMERICA MARKET SNAPSHOT
7.6.2 BRAZIL
7.6.3 ARGENTINA
7.6.4 REST OF SOUTH AMERICA
8 GLOBAL LIVER CANCER DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE
8.1 OVERVIEW
8.2 COMPANY MARKET RANKING
8.3 KEY DEVELOPMENT STRATEGIES
9 COMPANY PROFILES
9.1 ABBOTT LABORATORIES
9.1.1 OVERVIEW
9.1.2 FINANCIAL PERFORMANCE
9.1.3 PRODUCT OUTLOOK
9.1.4 KEY DEVELOPMENTS
9.2 BECTON DICKINSON & COMPANY
9.2.1 OVERVIEW
9.2.2 FINANCIAL PERFORMANCE
9.2.3 PRODUCT OUTLOOK
9.2.4 KEY DEVELOPMENTS
9.3 EPIGENOMICS AG
9.3.1 OVERVIEW
9.3.2 FINANCIAL PERFORMANCE
9.3.3 PRODUCT OUTLOOK
9.3.4 KEY DEVELOPMENTS
9.4 F. HOFFMANN-LA ROCHE LTD.
9.4.1 OVERVIEW
9.4.2 FINANCIAL PERFORMANCE
9.4.3 PRODUCT OUTLOOK
9.4.4 KEY DEVELOPMENTS
9.5 FUJIFILM MEDICAL SYSTEMS U.S.A., INC.
9.5.1 OVERVIEW
9.5.2 FINANCIAL PERFORMANCE
9.5.3 PRODUCT OUTLOOK
9.5.4 KEY DEVELOPMENTS
9.6 ILLUMINA, INC.
9.6.1 OVERVIEW
9.6.2 FINANCIAL PERFORMANCE
9.6.3 PRODUCT OUTLOOK
9.6.4 KEY DEVELOPMENTS
9.7 KONINKLIJKE PHILIPS N.V.
9.7.1 OVERVIEW
9.7.2 FINANCIAL PERFORMANCE
9.7.3 PRODUCT OUTLOOK
9.7.4 KEY DEVELOPMENTS
9.8 QIAGEN N.V.
9.8.1 OVERVIEW
9.8.2 FINANCIAL PERFORMANCE
9.8.3 PRODUCT OUTLOOK
9.8.4 KEY DEVELOPMENTS
9.9 SIEMENS HEALTHINEERS
9.9.1 OVERVIEW
9.9.2 FINANCIAL PERFORMANCE
9.9.3 PRODUCT OUTLOOK
9.9.4 KEY DEVELOPMENTS
9.10 THERMO FISHER SCIENTIFIC, INC.
9.10.1 OVERVIEW
9.10.2 FINANCIAL PERFORMANCE
9.10.3 PRODUCT OUTLOOK
9.10.4 KEY DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved